A new study found that the immunotherapy treatment worked against some types of cancers, allowing patients to avoid surgery ...

未来，邦耀生物将不断加强技术开发，克服行业壁垒进行多管线战略布局和技术整合，力求解决基因和细胞治疗中遇到的核心问题和卡脖子的技术难题，从而为更多遗传疾病、肿瘤疾病（特别是实体肿瘤）及自身免疫疾病等患者带来福音。

The development of second tumors is influenced by several factors. These include the type and intensity of treatment received ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

Some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

An immuno-based treatment targeting cancer cells with mismatch repair-deficiency could help those with the disease treat ...

Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Cancers with certain mutations can put the brakes on our immune system, allowing what's called a mismatch repair-deficient, or MMR-deficient, solid tumor to grow. The new treatment is an antibody ...